Results from a large post-marketing safety surveillance study in the Republic of Korea with a quadrivalent meningococcal CRM-conjugate vaccine in individuals aged 2 months-55 years

• Main Authors: Byung Wook Yoo (Author), Hye Lim Jung (Author), Yoon Seob Byeon (Author), Dong Ki Han (Author), Nak Yeong Jeong (Author), Carlo Curina (Author), Luca Moraschini (Author), Sung Jin Kim (Author), Chiranjiwi Bhusal (Author), Michele Pellegrini (Author), Yan Miao (Author)
• Format: Book
• Published: Taylor & Francis Group, 2020-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The quadrivalent meningococcal conjugate vaccine MenACWY-CRM is approved in the Republic of Korea for use in individuals from 2 months of age. This single-arm, open-label, observational, multicenter, post-marketing study (NCT01766206) assessed the safety of MenACWY-CRM vaccine administered according...